Haemonetics Corporation (HAE) Dividend History

Company News

• Global Blood Bank Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight

  The global blood bank market is expected to grow significantly from 2025 to 2032, driven by the rising incidence of blood disorders, chronic illnesses, and accidents, as well as advancements in blood bank technologies and increased awareness about blood donation.

  GlobeNewswire Inc.

  Featured Companies: ABT BIO BIO.B CAH TMO
• Is Phibro (PAHC) Stock Worth Retaining in Your Portfolio Now?

  Phibro Animal Health Corporation's robust sales of vaccines and medicated feed additives (MFAs) are driving growth in its Animal Health business. The company's focus on advancing nutritional specialties and vaccine technologies, along with a new vaccine production unit, instills optimism. However, adverse macroeconomic impacts and growing competition from generic alternatives are concerns.

  Zacks Investment Research

  Featured Companies: AVNS PAHC TFX
• Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst

  Needham & Co. analyst Mike Matson upgraded Haemonetics Corporation (NYSE:HAE) from Hold to Buy with a price target of $112. The analyst says that Haemonetics has reaffirmed its “high-20%” FY26 operating margin goal. To reach this, the company must improve by approximately 600 basis points from its FY24 margin of 21.1%, writes the analyst. While the analyst earlier doubted the company’s ability to reach this target, the product mix analysis has bolstered their confidence. The analyst has identified two key factors influencing the company’s gross margin, which includes ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: NBSM XHE
• 3 Undervalued Stocks to Buy as Optimism Persists Despite Rate-Cut Uncertainty

  Investing.com

  Featured Companies: CVX HES STM